Peter Sazani

Dr. Sazani brings 16 years research and development leadership experience, and has a passion for tackling rare genetic diseases. Prior to joining Enzerna, Dr. Sazani was the head of patient advocacy and medical affairs at Marathon Pharmaceuticals (Now PTC Therapeutics), helping guide the Duchenne community through the approval of Emflaza (deflazacort). Prior to Marathon, Dr. Sazani was Executive Director of Pre-clinical development and Medical Affairs at Sarepta Therapeutics. While there, Dr. Sazani conducted and oversaw the research, and subsequently all pre-clinical, clinical pharmacology and medical affairs activities related to Exondys (eteplirsen). Dr. Sazani was also heavily involved in negotiations with FDA regarding eteplirsen. Dr. Sazani joined Sarepta through the 2007 acquisition of Ercole Biotech, a company founded to commercialize Exon Skipping technology. Prior to that, Dr. Sazani was a post doctoral fellow at Harvard Medical School; he received his PhD in Pharmacology from The University of North Carolina at Chapel Hill.